Luke Basil Evnin
2 additional roles and seats, 4 additional attributed investments
Every relationship, signal and contact on this record, with the source on each.
Includes 3 days of DFX Intelligence. Then $199/month unless canceled.
Nothing material in the last 365 days. Last change: 12 Jul 2021, Latest Frontier Medicines Form D equity offering ($88.5M) on 12 Jul 2021.
- MPM Bioimpact MemberDec 1, 1999 to present · “Schedule A: EVNIN, LUKE, BASIL, MEMBER, since 12/1999, ownership D, control person N”Fact Form ADV
| Company | Round | Investor | Attribution | Date | Source |
|---|---|---|---|---|---|
| Frontier Medicines | Form D equity offering · $88.5M | MPM Bioimpact | strongly supported · board | Jul 12, 2021 | Inference sec.gov |
| Frontier Medicines | Form D equity offering · $33.5M | MPM Bioimpact | strongly supported · board | Jul 29, 2019 | Inference sec.gov |
| Potenza Therapeutics, Inc. | Form D equity offering · $5.0M | MPM Bioimpact | strongly supported · board | Dec 29, 2017 | Inference sec.gov |
- Frontier Medicines board seat on a deal Jul 12, 2021 Inference
- Potenza Therapeutics, Inc. board seat on a deal Dec 29, 2017 Inference
- Vesuvius Pharmaceuticals, Inc. board seat on a deal Jan 5, 2015 Inference
- Jul 12, 2021Form D equity offering in Frontier Medicines (MPM Bioimpact)
- Jul 29, 2019Form D equity offering in Frontier Medicines (MPM Bioimpact)
- Dec 29, 2017Form D equity offering in Potenza Therapeutics, Inc. (MPM Bioimpact)
- Dec 1, 1999Joined MPM Bioimpact as Member
Relationships across DFX
on 1 other DFX graph
Luke Basil Evnin is the same institution as 1 record in Private Equity.
The joined record opens with the product, beside every other relationship on this page.
Checking your plan…